title: Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.
abstract: Anti-CD20 monoclonal antibodies (mAbs), rituximab, ofatumumab and obinutuzumab, have a significant impact in the treatment of chronic lymphocytic leukemia (CLL), particularly in combination with chemotherapy. Over the last few years, several new mAbs have been developed and investigated in CLL. The most promising newer mAbs are directed against CD20, CD19, CD37 and CD40. Combinations of antibodies with targeted drugs like ibrutinib, idelalisib or lenalidomide will probably replace chemotherapy-based combinations in the near future. This review gives a critical overview of established mAbs as well as new antibodies potentially useful in CLL.
authors.affiliation: Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93-510 Lodz, Ul. Ciolkowskiego 2, Poland.
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Robak
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D019013:CD40 Antigens / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000628:therapy*; D059470:Tetraspanins / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D018941:Antigens, CD19; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; C059071:CD37 protein, human; D019013:CD40 Antigens; D059470:Tetraspanins
keywords: CD19; CD20; CD23; CD37; CD40; CD52; CLL; GA-101; MOR208; TRU-016; dacetuzumab; lucatumumab; lumiliximab; ocrelizumab; ofatumumab; otlertuzumab; veltuzumab